due
divers
biolog
activ
found
aquat
ecosystem
marin
metabolit
activ
area
drug
discoveri
last
year
marin
metabolit
found
inhibit
number
enzym
import
treatment
human
diseas
focu
marin
metabolit
inhibit
enzym
acetylcholinesteras
cellular
target
treatment
earlystag
alzheim
diseas
current
develop
anticholinesteras
drug
improv
potenc
drug
act
dual
acetylcholinesteras
aggreg
inhibitor
sought
treat
alzheim
diseas
seven
class
marin
metabolit
report
possess
anticholinesteras
activ
compar
metabolit
clinicallyus
acetylcholinesteras
inhibitor
known
mechan
inhibit
perform
dock
simul
compar
publish
experiment
data
metabolit
determin
like
mechan
inhibit
class
marin
inhibitor
result
indic
sever
marin
metabolit
bind
region
acetylcholinesteras
activ
site
bound
clinicallyus
drug
rivastigmin
galanthamin
donepezil
tacrin
use
novel
pose
adopt
comput
drug
design
tighter
bind
anticholinesteras
drug
like
act
inhibitor
acetylcholinesteras
activ
aggreg
inhibit
acetylcholinesteras
ach
member
hydrolas
fold
famili
enzym
enzym
degrad
excitatori
neurotransmitt
acetylcholin
ach
synapt
junction
extraordinarili
fast
catalyt
rate
order
rate
constant
almost
fast
diffusioncontrol
reaction
ach
degrad
cholin
acet
hydrolysi
mechan
result
decreas
signal
transmiss
nerv
synaps
use
xray
crystallographi
sussman
lab
elucid
resolut
structur
ach
torpedo
californica
electr
ray
two
site
particip
hydrolysi
reaction
ach
anion
site
esterat
site
anion
site
draw
ach
activ
site
follow
hydrolysi
esterat
site
catalyt
triad
lie
bottom
gorg
long
narrow
gorg
contain
conserv
aromat
residu
eg
lead
activ
site
residu
catalyt
triad
creat
esterat
site
residu
creat
anion
site
approxim
away
anion
site
anoth
neg
charg
site
call
peripher
anion
bind
site
pa
compos
residu
bind
substrat
inhibitor
pa
caus
conform
chang
ach
reduc
ach
abil
enter
activ
site
acetylcholinesteras
drug
target
treat
neural
degen
disord
alzheim
diseas
ad
ad
elderli
individu
character
memori
loss
difficulti
store
new
inform
behavior
cognit
difficulti
progress
natur
ad
requir
high
level
care
sinc
patient
lose
abil
perform
simpl
daili
function
two
hypothes
explain
patholog
ad
one
suggest
decreas
ach
product
within
synapt
junction
contribut
onset
ad
cholinerg
hypothesi
suggest
develop
toxic
peptid
aggreg
brain
contribut
progress
ad
amyloid
hypothesi
cholinerg
hypothesi
suggest
inhibit
ach
result
improv
cognit
increas
ach
activ
amyloid
hypothesi
suggest
drug
inhibit
amyloid
plaqu
format
slow
progress
ad
inestrosa
demonstr
pa
ach
form
stabl
complex
senil
plaqu
promot
format
peptid
aggreg
compound
bind
pa
ach
act
aggreg
inhibitor
therefor
ach
inhibitor
achei
shown
effect
prevent
ach
hydrolysi
plaqu
aggreg
ad
dualfunct
inhibitor
dfi
potenti
effect
singlefunct
inhibitor
current
clinic
ad
therapi
use
anticholinesteras
drug
rivastigmin
tacrin
galanthamin
donepezil
figur
bind
mode
drug
depict
supplementari
figur
inhibit
ach
increas
amount
prolong
durat
ach
present
synapt
junction
ach
allow
enter
nicotin
receptor
due
increas
ach
level
current
chemotherapeut
option
low
specif
toward
ach
poorli
toler
patient
patient
receiv
donepezil
show
moder
improv
symptom
ad
thu
develop
higher
affin
inhibitor
may
also
help
allevi
mental
impair
associ
ad
recent
inhibitor
inhibit
ach
prevent
aggreg
suggest
new
therapeut
rout
although
none
current
use
present
marin
natur
product
clinic
use
achei
given
past
success
drug
deriv
marin
organ
explor
marin
metabolit
mm
novel
lead
anticholinesteras
compound
may
identifi
new
compound
novel
interact
ach
garner
select
gain
potenc
treat
ad
purpos
articl
comparison
known
marinederiv
compound
anticholinesteras
activ
compound
whose
mechan
action
well
understood
identifi
similar
well
novel
properti
marin
compound
marin
metabolit
vari
greatli
structur
mass
chemic
composit
differ
class
mm
report
anticholinesteras
activ
sesquiterpen
acet
pyrrol
deriv
tetrazacyclopentazulen
bromotyrosin
deriv
plastoquinon
farnesylaceton
polyalkylpyridinium
polym
polyap
overal
metabolit
found
moder
level
anticholinesteras
activ
gener
inhibit
sever
differ
mechan
review
hostettmann
publish
acetylcholinesteras
inhibitor
known
point
includ
marin
origin
paper
includ
new
inhibitor
discov
marin
speci
sinc
hostettmann
review
detail
structur
inform
enzymeinhibitor
interact
focu
illustr
inhibitor
interact
within
ach
receptor
compar
compound
known
inhibit
mechan
incorpor
experiment
studi
literatur
molecular
ensembl
dock
studi
mm
ach
receptor
better
understand
molecular
interact
inhibitor
class
propos
novel
hybrid
compound
would
combin
best
synthet
mm
compound
compound
onchid
figur
sesquiterpen
acet
contain
aldehyd
acet
ester
isol
mucou
secret
binneyi
mollusk
speci
ireland
faulkner
onchid
shown
interact
acetylcholin
recognit
site
specif
esterat
site
found
k
dock
experi
onchid
shown
interact
esterat
site
ach
consist
abramson
work
three
pose
gener
onchid
supplementari
figur
three
pose
cyclohexan
ring
posit
bottleneck
surfac
ach
activ
site
residu
two
three
pose
acet
ester
oxyanion
hole
lowest
energi
pose
figur
onchid
gener
receptor
place
acet
ester
oxyanion
hole
aldehyd
acyl
pocket
onchid
cyclohexan
ring
bottleneck
creat
major
interact
potenti
hydrogen
bond
hbond
interact
oxyanion
hole
hydrophob
contact
bottleneck
possibl
hbond
catalyt
triad
figur
aldehyd
proteas
inhibitor
shown
interact
oxyanion
hole
provid
strong
inhibit
enzym
potenti
hbond
interact
oxyanion
hole
residu
ach
uniqu
marin
metabolit
vs
synthet
interact
oxyanion
hole
possibl
donepezil
galanthamin
tacrin
rivastigmin
dock
ach
hydroxyl
group
galanthamin
interact
water
molecul
locat
oxyanion
hole
residu
oxyanion
hole
onchid
dock
receptor
conserv
water
molecul
present
result
onchid
clockwis
rotat
prevent
steric
clash
water
molecul
supplementari
figur
ester
group
shift
backward
away
catalyt
serin
aldehyd
group
move
downward
may
initi
bind
mode
onchid
undergo
onchid
may
rotat
displac
water
oxyanion
hole
onchid
irrevers
inhibitor
coval
bond
form
ach
receptor
sever
reaction
mechan
onchid
inhibit
suggest
abramson
schiff
base
format
lysin
ii
attack
betaunsatur
carbon
conjug
aldehyd
cy
ly
tyr
iii
format
react
ly
form
pyrrol
coval
adduct
abramson
benefit
crystal
structur
ach
solv
sussman
limit
mechanist
analysi
ly
ach
locat
outsid
buri
insid
cy
ach
six
pair
involv
intrachain
disulfid
bond
last
near
activ
site
gorg
one
activ
site
locat
gorg
sever
tyr
locat
gorg
tyr
base
crystal
structur
abramson
find
probabl
mechan
attack
betaunsatur
carbon
conjug
aldehyd
tyr
howev
candid
tyr
mechan
identifi
dock
analysi
event
onchid
irrevers
inhibit
ach
make
unsuit
direct
use
anticholinesteras
inhibitor
human
diseas
sinc
perman
inhibit
ach
lead
potenti
deadli
cholinerg
toxic
could
potenti
use
insecticid
pesticid
onchid
interact
oxyanion
hole
new
mechanist
area
incorpor
ration
drug
design
novel
inhibitor
see
rapidithrix
thailandica
glide
bacterium
discov
seawe
extract
andaman
sea
coast
thailand
srisukchayakul
kanjanaopa
cowork
isol
pyrrol
deriv
marinoquinolin
figur
pyrrol
r
thailandica
marinoquinolin
extend
aromat
system
inhibit
ach
ic
valu
isol
metabolit
possess
anticholinesteras
activ
inact
pyrrol
deriv
isol
lack
extens
aromat
ring
system
structur
differ
suggest
inhibit
produc
marinoquinolin
due
stack
interact
prior
work
elucid
specif
residu
residu
aromat
gorg
marinoquinolin
potenti
stack
hypothes
marinoquinolin
interact
ach
particip
stack
similar
tacrin
mode
bind
observ
marinoquinolin
dock
figur
lowenergi
structur
ach
support
hypothesi
stack
aromat
residu
structur
crystal
tacrin
ligand
orient
approxim
upward
compar
posit
structur
supplementari
figur
upon
bind
tacrin
form
interact
inhibitor
dock
marinoquinolin
structur
gener
improv
score
kjmol
vs
three
ach
receptor
structur
tabl
suggest
bind
marinoquinolin
analog
tacrin
figur
dock
galanthamin
receptor
without
conserv
water
molecul
result
crystallograph
pose
select
inhibitor
gener
similar
score
pose
receptor
except
donepezil
receptor
onchid
best
pose
onchid
chosen
tetrazacyclopentazulen
two
main
pose
pose
score
denot
pose
score
denot
nd
sargaquino
acid
would
dock
receptor
due
ring
posit
occlud
activ
site
gorg
see
supplementari
figur
pigment
zoanthid
coral
vast
produc
tetrazacyclopentazulen
compound
tcp
figur
one
yellow
tcp
call
pseudozoanthoxanthinlik
compound
pzt
isol
turk
cowork
like
onchid
compound
shown
competit
acetylcholinesteras
inhibitor
k
unlik
onchid
interact
esterat
site
acetylcholinesteras
pzt
compound
found
interact
aromat
residu
line
activ
site
gorg
determin
fluoresc
emiss
spectroscopi
turk
cowork
found
signal
intrins
tryptophan
locat
gorg
acetylcholinesteras
quench
presenc
inhibitor
result
suggest
interact
trp
residu
inhibitor
mechan
inhibit
use
receptor
pose
pztcompound
score
kjmol
show
orient
consist
tstack
also
potenti
hbond
interact
oxyanion
hole
residu
figur
dock
pzt
compound
receptor
result
score
kjmol
posit
pzt
compound
stack
figur
pose
agreement
publish
experiment
data
suggest
interact
trp
residu
turk
cowork
could
determin
trp
residu
pzt
interact
dock
analysi
suggest
like
also
two
conserv
trp
residu
gorg
locat
entranc
acyl
pocket
howev
dock
analys
indic
close
associ
andor
pzt
compound
higher
energi
conform
form
interact
like
share
bind
mode
tacrin
one
propos
marinoquinolin
rotat
would
allow
doubl
stack
interact
figur
like
marinoquinolin
bind
score
improv
dock
receptor
kjmol
thu
pzt
like
form
interact
turn
close
bottleneck
prevent
ach
enter
acyl
pocket
tacrin
best
dock
score
kjmol
kjmol
weaker
pztcompound
bind
score
paper
use
indol
ring
donepezil
fuse
ring
tacrin
develop
potent
dual
site
ach
inhibitor
tacrin
moieti
bound
anion
site
replac
tacrin
moieti
pztcompound
ration
drug
design
potenti
increas
potenc
dual
inhibitor
even
see
ryu
choi
cowork
report
isol
seri
terpenoid
compound
figur
brown
alga
sargussum
sagamianum
four
compound
isol
alga
sargaquino
acid
ic
sargachromenol
ic
monooxofarnesylaceton
ic
dihydromonooxofarnesylaceton
ic
four
compound
moder
level
bovin
erythrocyt
ach
inhibit
specif
butyrylcholinesteras
base
sole
structur
comparison
hypothes
compound
like
inhibit
ach
two
way
stack
interact
aromat
residu
interact
esterat
site
date
experiment
work
done
probe
mechan
inhibit
plastoquinon
farnesylaceton
dock
two
plastoquinon
result
similar
bind
mode
figur
three
stack
interact
observ
dock
sargaquino
acid
quinon
moieti
sargaquino
acid
posit
next
ii
olefin
stack
iii
olefin
stack
sargaquino
acid
bind
score
best
metabolit
consid
kjmol
receptor
sargachromenol
one
less
stack
interact
dock
structur
sargaquino
acid
observ
reduc
quinon
moieti
sargachromenol
stack
doubl
bond
sargachromenol
stack
figur
sargachromenol
bind
slightli
weaker
receptor
sargaquino
acid
best
bind
score
kjmol
receptor
farnesylaceton
unlik
plastoquinon
share
similar
bind
mode
dihydromonooxofarnesylaceton
bind
score
kjmol
receptor
oxyanion
hole
keton
moieti
potenti
hbond
pa
unsatur
keton
posit
hbond
figur
compound
uniqu
famili
greatli
reduc
stack
interact
howev
like
sargaquino
acid
monooxofarnesylaceton
dock
structur
figur
bind
score
monooxofarnesylaceton
almost
kj
weaker
sargaquino
acid
kjmol
receptor
plastoquinon
farnesylaceton
like
competit
inhibitor
ach
occlud
activ
site
gorg
manner
similar
donepezil
protrud
somewhat
gorg
suggest
prevent
acetylcholin
enter
ach
bind
site
donepezil
stack
interact
locat
pa
plastoquinon
monooxofarnesylaceton
like
donepezil
primarili
use
stack
interact
stabil
receptor
ligand
complex
stack
within
gorg
isopren
unit
farnesylaceton
plastoquinon
right
number
linker
carbon
degre
flexibl
allow
particip
multipl
aromat
interact
simultan
gener
plastoquinon
farnesylaceton
bind
side
opposit
pa
entranc
gorg
except
dihydromonooxofarnesylaceton
hbond
pa
develop
dual
bind
site
inhibitor
bind
anion
site
peripher
anion
site
linker
need
span
length
gorg
linker
bind
strongli
gorg
would
greatli
increas
potenc
dual
site
inhibitor
mani
linker
use
thu
far
contain
amid
aliphat
chain
pyrimidin
ring
piperidin
ring
cyclic
aromat
structur
dock
studi
plastoquinon
bind
tighter
ach
donepezil
best
score
kjmol
farnesylaceton
come
close
behind
donepezil
terpen
type
linker
seem
bind
well
gorg
capit
multipl
stack
interact
thu
may
use
new
linker
consid
creation
dual
site
inhibitor
dihydromonooxofarnesylaceton
two
keton
residu
one
bind
oxyanion
hole
one
bind
pa
residu
therefor
suggest
new
diketon
scaffold
use
insight
dock
score
pose
marin
metabolit
propos
new
ach
inhibitor
candid
figur
hypothes
could
gener
new
compound
use
mm
scaffold
would
better
bind
score
would
abl
predict
pose
compound
base
dock
data
mm
precursor
use
compound
dock
receptor
tabl
show
dock
score
design
inhibitor
candid
eleven
twelv
compound
show
improv
dock
score
compar
donepezil
one
compound
best
dock
score
kj
show
less
favor
bind
ach
receptor
donepezil
best
compound
pzt
base
terpen
linker
indolin
ring
donepezil
top
inhibitor
candid
clogp
score
calcul
chembiodraw
comparison
clogp
valu
clinicallyus
drug
donepezil
indic
penetr
bloodbrain
barrier
candid
would
similar
use
marin
metabolit
start
point
develop
new
ach
inhibitor
scaffold
improv
dock
score
success
difficult
accur
predict
interact
would
receptor
found
sever
new
interact
employ
candid
compound
exampl
found
major
interact
marin
metabolit
best
inhibitor
candid
shown
figur
dock
score
kj
amino
group
pzt
compound
scaffold
may
potenti
hydrogen
bond
compound
quinon
moieti
sargaquino
acid
quinon
moieti
sargachromenol
indolin
ring
donepezil
also
found
potenti
hbond
discuss
pose
new
inhibitor
detail
highlight
import
featur
contribut
increas
potenc
compound
also
observ
orient
compound
could
exactli
opposit
hypothes
exampl
pztcompound
marinoquinolin
use
scaffold
effort
drive
consid
base
compound
anion
site
stack
interact
observ
precursor
addit
pzt
compound
terpenoid
scaffold
produc
pose
moieti
stack
expect
also
produc
pose
locat
peripheri
gorg
particip
stack
reaction
pa
produc
slightli
favor
dock
score
latter
pose
compar
former
kj
versu
kj
pose
show
improv
bind
ach
receptor
compar
mm
precursor
invers
orient
also
observ
compound
receptor
new
interact
observ
candid
adopt
expect
pose
overal
insight
obtain
dock
analysi
marin
metabolit
ach
provid
idea
sever
candid
structur
potenti
dual
function
inhibitor
exhibit
properti
like
make
better
antialzheim
drug
current
clinic
use
comput
evalu
delin
import
interact
inhibitor
receptor
mechan
inhibit
site
interact
unknown
dock
techniqu
perform
mani
biologicallyimport
receptor
use
predict
interact
ach
inhibitor
suggest
inhibitor
bind
mode
use
marvin
sketch
program
chem
axon
compound
convert
structur
initi
structur
energi
minim
perform
chimera
ucsf
use
perform
full
structur
minim
use
steepest
decent
follow
conjug
gradient
calcul
total
charg
molecul
add
remain
hydrogen
explicitli
defin
structur
dock
use
dock
analys
success
rate
dock
compar
flexx
glide
gold
default
paramet
use
throughout
flexibl
dock
analysi
except
number
orient
vari
cours
sever
dock
simul
orient
evalu
dock
simul
locat
minimum
particular
compound
incomplet
dock
orient
number
increas
dataset
four
acetylcholinesteras
structur
pdb
code
use
dock
analysi
activ
site
identifi
use
ligand
galanthamin
donepezil
tacrin
locat
crystal
structur
respect
defin
activ
site
clinicallyus
inhibitor
donepezil
place
activ
site
align
receptor
delet
receptor
receptor
box
use
dock
inhibitor
enzym
crystal
structur
gener
molecular
graphic
imag
use
ucsf
chimera
packag
marin
product
aplysamin
polyap
exclud
dock
analysi
sinc
aplysamin
alloster
site
inhibitor
polyap
larg
molecular
weight
polym
compound
discuss
paper
compound
dock
neutral
state
inhibitor
crystal
structur
ach
also
dock
ach
structur
includ
verifi
dock
algorithm
could
correctli
identifi
known
crystal
structur
pose
galanthamin
conserv
water
molecul
hydroxyl
group
hbond
dock
galanthamin
receptor
without
conserv
water
molecul
result
crystallograph
pose
select
inhibitor
gener
similar
score
receptor
except
donepezil
receptor
tabl
drastic
differ
donepezil
tacrin
receptor
result
residu
orient
interact
piperidin
moietya
critic
interact
inhibitor
dock
result
consist
observ
experiment
data
onchid
marinoquinolin
tetrazacyclopentazulen
compound
interact
ach
data
also
suggest
new
target
region
within
ach
receptor
potenti
structur
scaffold
novel
ach
inhibitor
reason
bind
mode
plastoquinon
farnesylaceton
bind
score
dock
analysi
could
accur
compar
literatur
inhibit
valu
determin
experiment
sinc
sever
report
valu
given
ic
unit
concentr
depend
concentr
enzym
use
perform
assay
alway
report
literatur
dock
score
intern
consist
explor
marin
metabolit
mm
option
lead
compound
may
identifi
new
use
interact
scaffold
increas
potenc
garner
select
compound
identifi
new
target
site
within
acetylcholinesteras
develop
achei
futur
gener
ad
drug
could
util
hbond
oxyanion
hole
residu
stack
interact
hbond
pa
inhibit
ach
develop
novel
acetylcholinesteras
inhibitor
characterist
mm
increas
number
protonat
nitrogen
atom
stack
creation
terpen
linker
dual
site
inhibitor
may
help
develop
compound
greater
potenc
optim
stack
interact
gorg
hypothet
structur
shown
figur
sever
properti
exhibit
mm
also
includ
design
dfi
prevent
ach
degrad
aggreg
overal
mm
bind
tighter
ach
galanthamin
tacrin
sever
metabolit
bind
tighter
donepezil
select
cross
scaffold
featur
mm
success
produc
compound
even
better
ach
bind
score
precursor
scaffold
use
yet
final
overal
pose
candid
compound
alway
expect
mani
compound
gener
interact
pa
site
critic
interact
contribut
inhibit
aggreg
determin
cholinesteras
isozym
specif
ach
versu
butrylcholinesteras
effect
aggreg
sesquiterpen
acet
pyrrol
deriv
pztcompound
plastoquinon
farnesylaceton
class
mm
describ
articl
would
provid
addit
guid
develop
novel
compound
therapi
alzheim
diseas
